國立虎尾科技大學 |

Discovering and Developing Molecules with Optimal Drug-Like Properties

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Discovering and Developing Molecules with Optimal Drug-Like Properties/ edited by Allen C Templeton, Stephen R. Byrn, Roy J Haskell, Thomas E. Prisinzano.
other author:	Templeton, Allen C.
Description:	XI, 511 p. 161 illus., 130 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Pharmaceutical technology. -
Online resource:	https://doi.org/10.1007/978-1-4939-1399-2
ISBN:	9781493913992

Discovering and Developing Molecules with Optimal Drug-Like Properties
Discovering and Developing Molecules with Optimal Drug-Like Properties[electronic resource] /edited by Allen C Templeton, Stephen R. Byrn, Roy J Haskell, Thomas E. Prisinzano. - 1st ed. 2015. - XI, 511 p. 161 illus., 130 illus. in color.online resource. - AAPS Advances in the Pharmaceutical Sciences Series,152210-7371 ;. - AAPS Advances in the Pharmaceutical Sciences Series,20.

1 Developability Assessment and Risk Management During Drug Discovery -- 2 Discovery Formulations – Approaches and Practices in Early Preclinical Development -- 3 Enabling Discovery Through Leveraging and Miniaturizing Pharmaceutical Principles and Processes -- 4 Diagnosing Biopharmaceutical Limitations -- 5 The Importance of Molecular Design Principles in Delivering High Quality Pharmaceutical Candidates -- 6 Predictive Approaches to Establishing, Understanding, and Communicating Risk with Emphasis on Early Development -- 7 Strategies and Methods for Drug Candidate Phase Optimization in Discovery Space -- 8 Efficient Laboratory Methods to Assess Risk and Design Formulations -- 9 Advanced X-ray Analytical Methods to Understand Structure, Properties and Risk -- 10 Performance and Characterization of Amorphous Solid Dispersions: An Overview -- 11 Hot-Melt Extrusion: The Process-Product-Performance Interplay -- 12 Practical Considerations for Spray Dried Formulation and Process Development -- 13 Nanosizing: “End-to-End” Formulation Strategy for Poorly-Water- Soluble Molecules -- 14 Leveraging Solid State Form and Physiochemical Properties for Early Clinical Formulation Efforts: Opportunities and Challenges during Telcagepant Liquid Capsule Development.

This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state properties and critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings.

ISBN: 9781493913992

Standard No.: 10.1007/978-1-4939-1399-2doiSubjects--Topical Terms:

557391
Pharmaceutical technology.

LC Class. No.: RS380

Dewey Class. No.: 615.19

Discovering and Developing Molecules with Optimal Drug-Like Properties
LDR:04128nam a22004215i 4500 001 963536
003 DE-He213
005 20200703225829.0
007 cr nn 008mamaa
008 201211s2015 xxu| s |||| 0|eng d
020 $a 9781493913992 $9 978-1-4939-1399-2
024 7 $a 10.1007/978-1-4939-1399-2 $2 doi
035 $a 978-1-4939-1399-2
050 4 $a RS380
050 4 $a RS190-210
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Discovering and Developing Molecules with Optimal Drug-Like Properties $h [electronic resource] / $c edited by Allen C Templeton, Stephen R. Byrn, Roy J Haskell, Thomas E. Prisinzano.
250 $a 1st ed. 2015.
264 1 $a New York, NY : $b Springer New York : $b Imprint: Springer, $c 2015.
300 $a XI, 511 p. 161 illus., 130 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 15
505 0 $a 1 Developability Assessment and Risk Management During Drug Discovery -- 2 Discovery Formulations – Approaches and Practices in Early Preclinical Development -- 3 Enabling Discovery Through Leveraging and Miniaturizing Pharmaceutical Principles and Processes -- 4 Diagnosing Biopharmaceutical Limitations -- 5 The Importance of Molecular Design Principles in Delivering High Quality Pharmaceutical Candidates -- 6 Predictive Approaches to Establishing, Understanding, and Communicating Risk with Emphasis on Early Development -- 7 Strategies and Methods for Drug Candidate Phase Optimization in Discovery Space -- 8 Efficient Laboratory Methods to Assess Risk and Design Formulations -- 9 Advanced X-ray Analytical Methods to Understand Structure, Properties and Risk -- 10 Performance and Characterization of Amorphous Solid Dispersions: An Overview -- 11 Hot-Melt Extrusion: The Process-Product-Performance Interplay -- 12 Practical Considerations for Spray Dried Formulation and Process Development -- 13 Nanosizing: “End-to-End” Formulation Strategy for Poorly-Water- Soluble Molecules -- 14 Leveraging Solid State Form and Physiochemical Properties for Early Clinical Formulation Efforts: Opportunities and Challenges during Telcagepant Liquid Capsule Development.
520 $a This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state properties and critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings.
650 0 $a Pharmaceutical technology. $3 557391
650 1 4 $a Pharmaceutical Sciences/Technology. $3 768561
700 1 $a Templeton, Allen C. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1063048
700 1 $a Byrn, Stephen R. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1177527
700 1 $a Haskell, Roy J. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1258552
700 1 $a Prisinzano, Thomas E. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1258553
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9781493914005
776 0 8 $i Printed edition: $z 9781493913985
776 0 8 $i Printed edition: $z 9781493948604
830 0 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20 $3 1255084
856 4 0 $u https://doi.org/10.1007/978-1-4939-1399-2
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)